bullish
Symbio Confirms Treakisym’s In-House Commercialization Post Patent Expiration in 2020e
257 Views16 Oct 2018 18:22
Significantly reduces execution risk for an operational turnaround in 2021e
As highlighted in previous notes ("Symbio Pharma (4582 JP) - Gross...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Symbio Confirms Treakisym’s In-House Commercialization Post Patent Expiration in 2020e16 Oct 2018
- Treakisym to Be Used as a Pre-Treatment To CAR-T Therapy28 Sep 2018
- Growth Drivers on Track – Operational Turnaround Expected in 202130 Aug 2018
- Symbio Pharma (4582 JP) - Gross Margin Expansion Led Operational Turnaround in 202105 Apr 2018
x